Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Position Raised by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 475,606 shares of the company's stock after acquiring an additional 22,355 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Teva Pharmaceutical Industries were worth $10,482,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the company. Atria Investments Inc increased its holdings in shares of Teva Pharmaceutical Industries by 135.4% in the 3rd quarter. Atria Investments Inc now owns 30,856 shares of the company's stock valued at $556,000 after purchasing an additional 17,746 shares during the period. Venturi Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $60,000. Victory Capital Management Inc. increased its stake in Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Victory Capital Management Inc. now owns 1,928,715 shares of the company's stock valued at $34,755,000 after buying an additional 21,764 shares during the period. Oppenheimer & Co. Inc. lifted its position in Teva Pharmaceutical Industries by 68.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 32,402 shares of the company's stock worth $584,000 after buying an additional 13,215 shares in the last quarter. Finally, D Orazio & Associates Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $199,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on TEVA shares. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday, March 7th. Barclays reduced their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Bank of America dropped their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Finally, UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $16.50 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a market cap of $18.70 billion, a price-to-earnings ratio of -11.38, a P/E/G ratio of 1.44 and a beta of 0.82. The business's 50-day simple moving average is $18.38 and its 200-day simple moving average is $18.31. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.